Ref.: BL-RE-092512Manufacturer ref.: EB8RBX10 10 x 96 tests
Price on request
Custom pricing depending on configuration and quantity.
The interleukin-1 beta is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. L的IL-1 beta is synthesized in response to inflammatory stimuli as a 31 kDa inactive proform that is...
The interleukin-1 beta is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. L的IL-1 beta is synthesized in response to inflammatory stimuli as a 31 kDa inactive proform that is...
The interleukin-1 beta is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. L的IL-1 beta is synthesized in response to inflammatory stimuli as a 31 kDa inactive proform that accumulates in cytosol. The cleavage of pro-IL-1 beta in the active 17 kDa protein requires the activation of inflammasomas, which are multiprotein complexes that respond to pathogens, stress conditions and other hazard signals. Activation of the inflammasoma triggers the treatment of the precursor of caspase-1 in its active form, which in turn cleaves the pro-IL-1 beta. L的IL-1 beta does not have a signal sequence peptide for the conventional ER/Golgi pathway. It is secreted along the caspase-1 via an alternative mechanism and understood incompletely. Although the beta-IL-1 is most often secreted as active, the secretion of the uncleavened protein can be detectable under certain biological conditions. The signals of the IL-1 beta via two receptors, IL-1RI and IL-1RII, are both shared with l的IL-1 alpha. The activity of the IL-1 beta may be moderated by the IL-1 receptor antagonist, a protein produced by many types of cells that block receptor binding by competitive inhibition. The role of the beta-IL-1 is important in the defence of the innate host by triggering the production of other proinflammatory cytokines in the target cells and by triggering acute phase responses to infection and injury. High levels of d的IL-1 beta have been associated with many chronic inflammatory conditions of the beta-IL-1 neutralizing the potential therapeutic value of antibodies.
Sensitivity
Sensitivity of the dosage: 0.85 pg/ml.
Measurement range
Dose range: 0.85 to 200 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Coefficient of intradose variation < 10%, interdose < 12%.
Target
Target: IL-1 beta.
Technical specifications
General
Brand
Invitrogen
Supplier ref. (Fisher Scientific)
17737503
Specifications
Accession number
P09428
Dose range
0.85 to 200 pg/ml
Sensitivity of the dosage
0.85 pg/ml
Conjugate
Biotin
Product type
ELISA
Type of sample
Plasma, Serum, Surnatant
For use with (equipment)
Colorimetric microplate reader
Genetic identification (Enter)
281251
Gene symbol(s)
IL1B
Coefficient of inter-dose variation
< 12%
Coefficient of intra-dose variation
< 10%
Contents of kits
96-well pre-coated sheetings, etc., at the same time as the pre-casting plate, at the same time as the pre-casting plate.
Marker or dye
HRP
Quantity
10 x 96 tests
Regulatory status
RUO
Target
IL-1 beta
Test time
1 h 20 min
Physical characteristics
Volume of sample
Serum, 50 μl-Plasma, 50 μl-Surnatant, 50 μl
Storage and shipping
Storage conditions
2°C to 8°C
Total duration of dosing
4 h 45 min
Origin and customs
Manufacturer ref.
EB8RBX10
Country of origin
United States
HS customs code
3002 12 00 00
A question or a specific configuration? Contact us for a quote.